Could a $4 blood pressure pill boost brain energy in Parkinson's?
NCT ID NCT07464028
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests whether terazosin, a drug already used for high blood pressure, can improve energy production in the brains of people with Parkinson's disease. Researchers will measure changes in a key energy molecule (ATP) in 120 participants over 1.5 years. If it works, it could lead to a new approach to slow the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Terazosin (a drug that may boost energy production in cells)
What this could lead to
If successful, this could point toward a new way to slow Parkinson's progression by improving how brain cells produce energy.
What could go wrong
This is an early Phase 2 trial with only 120 people. It tests a biological marker (ATP), not yet whether patients feel better. The drug may not show clear benefits or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE (PD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••